| David Michael Stark, MD | |
|
1749 Pine St, Abilene, TX 79601-3043 | |
| (325) 672-4372 | |
| (325) 673-0856 |
| Full Name | David Michael Stark |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 41 Years |
| Location | 1749 Pine St, Abilene, Texas |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730115908 | NPI | - | NPPES |
| 097197003 | Medicaid | TX | |
| 8S1531 | Other | TX | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | G5644 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Encompass Health Home Health | Abilene, TX | Home health agency |
| Kinder Hearts Home Health | Abilene, TX | Home health agency |
| Hendrick Medical Center | Abilene, TX | Hospital |
| Eastland Memorial Hospital | Eastland, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hendrick Provider Network | 9739162181 | 231 |
| The West Texas Rehabilitation Center | 2860301215 | 361 |
News Archive
Assistant U.S. attorneys in districts with high private salaries are more likely to take a drug-trafficking case to trial than are assistant attorneys in districts with low private salaries, according to a study by economists at Rice University and Colgate University that is published in the October issue of the Journal of Law and Economics.
Sunesis Pharmaceuticals, Inc. today reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules.
A team from the Centre for Automation and Robotics (CAR, UPM-CSIC) has developed a robotic exoskeleton that performs more efficiently rehabilitation therapies of patients with shoulder injuries. By using strength and motion sensors, the system assesses the degree of an injury and its evolution as the treatment progresses.
A novel anticancer molecule created by researchers at The Wistar Institute showed therapeutic activity in preclinical models of various cancer types.
› Verified 2 days ago
| Entity Name | Hendrick Provider Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396961322 PECOS PAC ID: 9739162181 Enrollment ID: O20040609001047 |
News Archive
Assistant U.S. attorneys in districts with high private salaries are more likely to take a drug-trafficking case to trial than are assistant attorneys in districts with low private salaries, according to a study by economists at Rice University and Colgate University that is published in the October issue of the Journal of Law and Economics.
Sunesis Pharmaceuticals, Inc. today reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules.
A team from the Centre for Automation and Robotics (CAR, UPM-CSIC) has developed a robotic exoskeleton that performs more efficiently rehabilitation therapies of patients with shoulder injuries. By using strength and motion sensors, the system assesses the degree of an injury and its evolution as the treatment progresses.
A novel anticancer molecule created by researchers at The Wistar Institute showed therapeutic activity in preclinical models of various cancer types.
› Verified 2 days ago
| Entity Name | Abilene Bone & Joint Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699701870 PECOS PAC ID: 6800876368 Enrollment ID: O20040723001006 |
News Archive
Assistant U.S. attorneys in districts with high private salaries are more likely to take a drug-trafficking case to trial than are assistant attorneys in districts with low private salaries, according to a study by economists at Rice University and Colgate University that is published in the October issue of the Journal of Law and Economics.
Sunesis Pharmaceuticals, Inc. today reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules.
A team from the Centre for Automation and Robotics (CAR, UPM-CSIC) has developed a robotic exoskeleton that performs more efficiently rehabilitation therapies of patients with shoulder injuries. By using strength and motion sensors, the system assesses the degree of an injury and its evolution as the treatment progresses.
A novel anticancer molecule created by researchers at The Wistar Institute showed therapeutic activity in preclinical models of various cancer types.
› Verified 2 days ago
| Entity Name | Hendrick Clinic Billing Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528644937 PECOS PAC ID: 9436559606 Enrollment ID: O20210609000931 |
News Archive
Assistant U.S. attorneys in districts with high private salaries are more likely to take a drug-trafficking case to trial than are assistant attorneys in districts with low private salaries, according to a study by economists at Rice University and Colgate University that is published in the October issue of the Journal of Law and Economics.
Sunesis Pharmaceuticals, Inc. today reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules.
A team from the Centre for Automation and Robotics (CAR, UPM-CSIC) has developed a robotic exoskeleton that performs more efficiently rehabilitation therapies of patients with shoulder injuries. By using strength and motion sensors, the system assesses the degree of an injury and its evolution as the treatment progresses.
A novel anticancer molecule created by researchers at The Wistar Institute showed therapeutic activity in preclinical models of various cancer types.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Michael Stark, MD 1749 Pine St, Abilene, TX 79601-3043 Ph: (325) 672-4372 | David Michael Stark, MD 1749 Pine St, Abilene, TX 79601-3043 Ph: (325) 672-4372 |
News Archive
Assistant U.S. attorneys in districts with high private salaries are more likely to take a drug-trafficking case to trial than are assistant attorneys in districts with low private salaries, according to a study by economists at Rice University and Colgate University that is published in the October issue of the Journal of Law and Economics.
Sunesis Pharmaceuticals, Inc. today reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules.
A team from the Centre for Automation and Robotics (CAR, UPM-CSIC) has developed a robotic exoskeleton that performs more efficiently rehabilitation therapies of patients with shoulder injuries. By using strength and motion sensors, the system assesses the degree of an injury and its evolution as the treatment progresses.
A novel anticancer molecule created by researchers at The Wistar Institute showed therapeutic activity in preclinical models of various cancer types.
› Verified 2 days ago
Samuel Scott Maroney, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2074 Antilley Rd, Abilene, TX 79606 Phone: 325-698-3865 | |
Dr. Paul W. Meriwether, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 950 N 19th St, Suite 201, Abilene, TX 79601 Phone: 325-672-3688 Fax: 325-673-2490 | |
Jeremy Blaine Britten, M.D. Orthopedic Surgery Medicare: May Accept Medicare Assignments Practice Location: 1633 Cottonwood St, Abilene, TX 79601 Phone: 325-672-4372 | |
Jared Johnson, PA Orthopedic Surgery Medicare: May Accept Medicare Assignments Practice Location: 1888 Antilley Rd Ste 200, Abilene, TX 79606 Phone: -- | |
Dr. Clifford L Deprang, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2074 Antilley Rd, Abilene, TX 79606 Phone: 325-698-3865 Fax: 325-793-1295 | |
Dr. Paul Wilkinson Mcdonough, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1701 Pine St, Abilene, TX 79601 Phone: 325-677-6219 Fax: 325-677-0129 | |
Dale A Funk, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2074 Antilley Rd, Abilene, TX 79606 Phone: 325-698-3865 Fax: 325-793-1295 |